Rexahn Pharmaceuticals announced that preliminary data from a Phase 2a clinical trial of RX-5902 in metastatic triple negative breast cancer, or TNBC, and updated data from the Phase 2a trial of RX-3117 in advanced bladder cancer were presented at the American Society of Clinical Oncology, or ASCO, 2018 annual meeting on June 2, 2018.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.